A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
← catalyst calendarNCT04161898 · readout ≤ 743 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
56estimated
Sites
48
Countries
Argentina, Brazil, China +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-02-04 | actual | When the study began enrolling |
| Primary completion | Aug 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Takayasu Arteritis (TAK)
Interventions
- Drug: Upadacitinib — also filed as ABT-494, RINVOQ
- Drug: Placebo for Upadacitinib
- Drug: Prednisolone
Primary outcomes
what the primary-completion date above is the date OFTime to First Relapse of Takayasu Arteritis (TAK) From Baseline through End of the Double-Blind (DB) Period
measured Up to occurrence of 40 events (approximately 52 months)
Number of Participants with Adverse Events (AEs)
measured Up to approximately 58 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed